GI CANCERS

Primary liver cancer death rates vary by region, and much is still to be done in the area of health equity.

NUC-1031, a drug for the first-line treatment of patients with advanced biliary tract cancer, has been granted fast track designation by the FDA.

The FDA has accepted a supplemental biologic application for nivolumab plus ipilimumab and chemotherapy as a potential treatment option for unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma.

GenesisCare and Lee Health announce their efforts to transform pancreatic patient survival rates in Florida.

Michael D. Chuong, MD, a radiation oncologist and medical director of Proton Therapy at Miami Cancer Institute, Baptist Health South Florida, discusses the benefits of MRI-guided radiation therapy in pancreatic cancer.

Complete surgical removal of a pancreatic tumor is not possible for most patients. Chemotherapy and radiation therapy are typically recommended to slow tumor growth, but ultimately are not expected to be curative, writes Michael Chuong, MD.

John Marshall, MD, speaks on regorafenib sequencing and relays his thoughts on the future of treatment for metastatic colorectal cancer.

Dr Marshall discusses the impact regorafenib has had in the treatment of metastatic colorectal cancer and describes data from the CORRECT and ReDOS clinical trials.

A gastrointestinal cancers expert describes monitoring strategies for progression of metastatic colorectal cancer.

Dr Marshall explains the different frontline treatment options for metastatic colorectal cancer, as well as maintenance therapy.

John Marshall, MD, provides an overview of the colorectal cancer landscape.

The FDA has accepted the biologics license application for tislelizumab, an anti-PD-1 immune checkpoint inhibitor for the treatment of unresectable recurrent locally advanced or metastatic esophageal squamous cell carcinoma in previously treated patients.

Patients with inoperable intrahepatic cholangiocarcinoma have demonstrated tendency to live longer when elective internal radiation therapy with Y90 is added to chemotherapy.

In an interview with Targeted Oncology™, Cathy Eng, MD, FACP, FASCO, discussed existing and novel biomarkers in anal cancer and ongoing research in the space.

Gavocabtagene autoleucel has been granted orphan drug designation from the FDA and is being investigated in other solid tumors in a phase 1/2 clinical trial.

For patients with neuroendocrine tumors, the chances of dying of cancer were higher than dying of other causes, but mortality largely varies by primary tumor site.

Following the successful completion of the phase 1b analysis, the study of devimistat in combination with gemcitabine and cisplatin in biliary tract cancer has moved on to phase 2.

To accompany a newly approved targeted therapy for IDH1-mutated cholangiocarcinoma, the Oncomine Dx Target Test has been approved as a companion diagnostic.

In an interview with Targeted Oncology™, Guru Sonpavde, MD, discussed the safety and efficacy of fixed-dose durvalumab for UTC along with an overview of the ongoing CheckMate 274 trial, which evaluates nivolumab compared to placebo in this patient population. 

Sintilimab in combination with the chemotherapy agents oxaliplatin and capecitabine improved overall survival in patients with unresectable, locally advanced, recurrent, or metastatic gastric or gastroesophageal junction adenocarcinoma compared with chemotherapy alone, reaching the predefined primary end point of the phase 2 ORIENT-16 clinical trial.

The first patient has been dosed in a phase 1b/2 trial of AVB-500, a therapeutic recombinant fusion protein, in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic adenocarcinoma.

In an interview with Targeted Oncology, Thierry Alcindor, MD, discusses the benefits of adding avelumab to perioperative chemotherapy for the treatment of gastroesophageal cancer in greater detail.

Cathy Eng, MD, FACO, FASCO, discusses how biomarkers are being explored to aid the treatment of anal cancers.

The FDA issued a complete response letter to Incyte Corporation in response to the Biologics License Application for the PD-L1 inhibitor, retifanlimab for the treatment of adult patients with locally advanced or metastatic squamous cell carcinoma of the anal canal who have progressed on, or who are intolerant of, platinum-based chemotherapy.

IMPROVED OVERALL and progres-sion-free survival rates were reported for the maintenance frontline combination of avelumab and best supportive care versus BSC alone across subgroups of patients with advanced urothelial cancer.